Cargando…

Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)

OBJECTIVES: SARS-CoV-2 is primarily transmitted within households, with massive healthcare system burdens. The role of inactivated vaccines and ChAdOx1 nCoV-19 vaccination in the prevention of within-household transmission remains unknown. METHODS: This observational case-control study tracked 408 S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muadchimkaew, Marisa, Siripongboonsitti, Taweegrit, Wongpatcharawarakul, Saowanee, Boonsankaew, Chanyapak, Tawinprai, Kriangkrai, Soonklang, Kamonwan, Mahanonda, Nithi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514960/ https://www.ncbi.nlm.nih.gov/pubmed/36180032 http://dx.doi.org/10.1016/j.ijid.2022.09.032

Ejemplares similares

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Transmissibility of SARS-CoV-2 Variants as a Secondary Attack in Thai Households: a Retrospective Study
por: Watanapokasin, Natcha, et al.
Publicado: (2021)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study
por: Nontawong, Nuttakant, et al.
Publicado: (2022)

Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV)
por: Siripongboonsitti, Taweegrit, et al.
Publicado: (2023)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study
por: Siripongboonsitti, Taweegrit, et al.
Publicado: (2023)

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population
por: Sirisreetreerux, Supamas, et al.
Publicado: (2023)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
por: Porntharukchareon, Thachanun, et al.
Publicado: (2023)

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
por: Thonginnetra, Saraiorn, et al.
Publicado: (2022)

Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
por: Thookhamme, Chayapa, et al.
Publicado: (2023)

Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Rangsrisaeneepitak, Vimonsri, et al.
Publicado: (2022)

Duration of Hepatitis B Vaccine-Induced Protection among Medical Students and Healthcare Workers following Primary Vaccination in Infancy and Rate of Immunity Decline
por: Phattraprayoon, Nanthida, et al.
Publicado: (2022)

SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand
por: Ungtrakul, Teerapat, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
por: Dechates, Bothamai, et al.
Publicado: (2023)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Lodge, Archie
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
por: Limpawittayakul, Piyarat, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply
por: Voysey, Merryn, et al.
Publicado: (2020)

A preliminary study on the effectiveness of maternal to neonatal transfer of antibodies against SARS-CoV-2 in the women vaccinated with heterologous CoronaVac–ChAdOx1
por: Pongsatha, Saipin, et al.
Publicado: (2023)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers
por: Kale, Pratibha, et al.
Publicado: (2021)

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield(TM)) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
por: Murali, Sharan, et al.
Publicado: (2022)

Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination
por: Kwon, Hyeryung, et al.
Publicado: (2021)

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination
por: Spataro, Rossella, et al.
Publicado: (2022)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Schultz, Nina H., et al.
Publicado: (2021)

367. Role of Conventional Biomarker for Prediction of Chest CT-confirmed COVID-19 Pneumonia
por: Harnphadungkit, Monprach, et al.
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Sinopharm’s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2
por: Abdelhafiz, Ahmed Samir, et al.
Publicado: (2022)

Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
por: Rogawski McQuade, Elizabeth T, et al.
Publicado: (2021)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

Takotsubo (stress) cardiomyopathy after ChAdOx1 nCoV-19 vaccination
por: Crane, Phillip, et al.
Publicado: (2021)

Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine
por: Lee, Hui Ping, et al.
Publicado: (2021)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
por: Ogbe, Ane, et al.
Publicado: (2022)

Post ChAdOx1 nCoV-19 vaccination frontal lobe syndrome
por: Tapdia, Madhusudan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f7gud1lu6j794d7qrr3tdldivq